Results 251 to 260 of about 114,609 (356)

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paltusotine is a novel, nonpeptide, selective somatostatin receptor 2 agonist in development for the treatment of acromegaly and carcinoid syndrome. This study investigated the mass balance, routes of excretion, absolute bioavailability and metabolite profile of orally administered paltusotine.
Rosa Luo   +6 more
wiley   +1 more source

Putting placebos to the test. [PDF]

open access: yesPLoS Biology, 2017
Liza Gross
doaj   +1 more source

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract The development of humanized IgG1 anti‐amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease‐modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, which gained marketing approval by the United States Food and Drug Administration (US FDA) in July 2023, has ...
Amy Bobbins   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy